LINCOLN PHARMA LTD Fair Value
LINCOLN · Healthcare · Current price ₹614.3
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹392 | 12% ROE fading to 12% over ~10 yrs, on ₹378 book |
| Relative P/E | ₹1,330 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹611 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is LINCOLN PHARMA LTD undervalued?
DocStoX estimates the fair value of LINCOLN PHARMA LTD at ₹690 per share, versus the current market price of ₹614. That puts the stock about +12.3% below our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹392), Relative P/E (₹1,330), Graham floor (₹611). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹392 (bear) to ₹690 (base) to ₹1,330 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on LINCOLN PHARMA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.